查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1134516

幻覺劑的全球市場:現狀分析與預測(2022年～2028年)

Psychedelic Drugs Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 154 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球幻覺劑的市場規模在預測期間(2022年～2028年)中預計將以約6％的年複合成長率成長。公眾對心理健康的認識不斷提高，尋找新療法的研發活動增加，以及精神疾病病例數量的激增正在推動致幻劑市場的增長。

本報告提供全球幻覺劑市場的相關調查，提供市場洞察，市場趨勢，競爭模式，企業概要等全面性資訊。

目錄

第1章 市場簡介

  • 市場定義
  • 主要目的
  • 相關利益者
  • 限制

第2章 調查方法或假設

  • 幻覺劑市場調查流程
  • 幻覺劑市場調查手法
  • 受訪者簡介

第3章 市場摘要

第4章 摘要整理

第5章 幻覺劑市場的COVID-19影響

第6章 幻覺劑市場收益(2020年～2028年)

第7章 市場洞察:各類醫藥品

  • 麥角酸二乙胺 (LSD)
  • 伽馬羥基丁酸 (GHB)
  • 氯胺酮
  • 賽洛西賓
  • 其他

第8章 市場洞察:各用途

  • 反抗性憂鬱症
  • 鴉片上癮
  • 創傷後壓力症候群
  • 恐慌症
  • 其他

第9章 市場洞察:各流通管道

  • 醫院藥局
  • 零售藥局
  • 其他

第10章 市場洞察:各地區

  • 北美
    • 美國
    • 加拿大
    • 其他的北美
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他的亞太地區
  • 全球其他地區

第11章 幻覺劑市場動態

  • 推動市場要素
  • 市場課題
  • 影響分析

第12章 幻覺劑市場機會

第13章 幻覺劑市場趨勢

第14章 需求面和供給面的分析

  • 需求面分析
  • 供給面分析

第15章 價值鏈分析

第16章 競爭模式

  • 競爭情形
    • 波特的五力分析

第17章 公司概要

  • Jazz Pharmaceuticals plc
  • Hikma Pharmaceuticals plc
  • Celon Pharma SA
  • Cybin Corp.
  • Pfizer Inc.
  • Numinus Wellness Inc.
  • F. Hoffmann-La Roche Ltd.
  • Avadel Pharmaceuticals PLC
  • PharmaTher Inc.
  • NRX Pharmaceuticals Inc.

第18章 免責聲明

簡介目錄
Product Code: UMHE211160

Global Psychedelic Drugs Market is expected to grow at a significant rate of around 6% during the forecast period. Psychedelic drugs are a class of psychoactive drugs that can produce changes in perception, mood, and cognitive processes. The global psychedelic drugs market is anticipated to witness an uptick owing to the growing awareness among the population regarding mental health, increasing research & development activities for exploring novel treatment options, and a rapid increase in the number of cases of depression, stress, and other mental disorders. For instance, in 2019, nearly 264 million people were suffering from depression and about 50 million people were suffering from dementia across the globe. Also, according to the National Council for Mental Wellbeing, almost half of the adults (46.4%) will suffer from a mental health disorder in their lifetime, and nearly 43.8 million adults (18 years or older) experience a mental illness at any one year. Furthermore, the increasing need for handling excess stress, anxiety, and other mental disorders along with the availability of off-label drugs in the market are also some of the factors that are positively influencing the psychedelic drugs market across the globe.

Jazz Pharmaceuticals plc, Hikma Pharmaceuticals plc, Celon Pharma SA, Cybin Corp., Pfizer Inc., Numinus Wellness Inc., F. Hoffmann-La Roche Ltd., Avadel Pharmaceuticals PLC, PharmaTher Inc., NRX Pharmaceuticals Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with drugs.

 

Insights Presented in the Report:

"Amongst drugs, LSD category to witness higher CAGR during the forecast period"

Based on drugs, the psychedelic drugs market is segmented into lysergic acid diethylamide (LSD), gamma-hydroxybutyric acid (GHB), ketamine, psilocybin, and others. The lysergic acid diethylamide segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe owing to its ability to increase social interaction, as per a study performed by Researchers from McGill University. Also, LSD is effective in reducing symptoms of stress-related anxiety and depression which in turn is also contributing to the growth of this segment.

"Amongst application, resistant depression to hold a significant share in the market in 2020"

Based on application, the psychedelic drugs market is classified into resistant depression, opiate addiction, post-traumatic stress disorder, panic disorders, and others. The resistant depression segment grabbed a significant market share in 2020. The growth of this segment can be attributed to the increase in the number of people not responding adequately to at least one antidepressant trial of adequate doses and duration.

"Amongst distribution channels, hospital pharmacies to hold a significant share in the market in 2020"

Based on distribution channels, the market is fragmented into hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies to hold a significant share in the market in 2020. This is mainly due to the increasing preference of the patients to avail treatment in hospitals and the easy availability of the medication in hospital pharmacies. Also, the tendency of consumers to visit hospital pharmacies for safe and authorized drugs is also driving the growth of this segment.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the psychedelic drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The major factors such as an increase in the population with mental disorders, a rise in investments in research and development for these drugs coupled with technological advancements and raising awareness regarding mental health among the population in the region. As per the National Institute of Mental Health (NIMH) statistics, in 2020, an estimated 52.9 million adults aged 18 or older in the United States had a mental illness.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global psychedelic drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Psychedelic Drugs Market
  • 2.2. Research Methodology of the Psychedelic Drugs Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PSYCHEDELIC DRUGS MARKET

6 PSYCHEDELIC DRUGS MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY DRUGS

  • 7.1. Lysergic Acid Diethylamide (LSD)
  • 7.2. Gamma Hydroxybutyric Acid (GHB)
  • 7.3. Ketamine
  • 7.4. Psilocybin
  • 7.5. Others

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Resistant Depression
  • 8.2. Opiate Addiction
  • 8.3. Post-traumatic Stress Disorder
  • 8.4. Panic Disorders
  • 8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 PSYCHEDELIC DRUGS MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 PSYCHEDELIC DRUGS MARKET OPPORTUNITIES

13 PSYCHEDELIC DRUGS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

  • 16.1. Competitive Landscape
    • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

  • 17.1. Jazz Pharmaceuticals plc
  • 17.2. Hikma Pharmaceuticals plc
  • 17.3. Celon Pharma SA
  • 17.4. Cybin Corp.
  • 17.5. Pfizer Inc.
  • 17.6. Numinus Wellness Inc.
  • 17.7. F. Hoffmann-La Roche Ltd.
  • 17.8. Avadel Pharmaceuticals PLC
  • 17.9. PharmaTher Inc.
  • 17.10. NRX Pharmaceuticals Inc.

18 DISCLAIMER